Additionally, there are few effective adjuvant therapy options for this group and for the so-called triple-negative (TNP) breast cancers that lack expression of ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). The gene discussed is ESR1; the disease is breast carcinoma.